Document is current
Any future updates will be listed below
-
Authors
Korobelnik, Jean-François https://orcid.org/0000-0002-4438-9535
Daien, Vincent
Faure, Céline https://orcid.org/0000-0002-7435-7518
Tadayoni, Ramin https://orcid.org/0000-0001-5616-3579
Giocanti-Aurégan, Audrey https://orcid.org/0000-0002-7918-7845
Dot, Corinne https://orcid.org/0000-0003-4398-3978
Kodjikian, Laurent https://orcid.org/0000-0002-3908-6716
Massin, Pascale
,
Faure, Céline
Tadayoni, Ramin
Giocanti-Aurégan, Audrey
Dot, Corinne
Kodjikian, Laurent
Massin, Pascale
Abada, Samir
Akesbi, Jad
Akninb, Isabelle
Alfonsi, Nicolas
Allieu, Sandrine
Arndt, Carl
Atmani, Karim
Baillif, Stephanie
Benouaich, Xavier
Benzerroug, Mounir
Béral, Laurence
Bodaghi, Barham
Bonicel, Pierre
Bourhis, Alexandre
Cartry, Guilhem
Chiambaretta, Frédéric
Chiquet, Christophe
Creuzot-Garcher, Catherine
Darugar, Adil
De Bats, Flore
Delyfer, Marie-Noelle
Di Nolfo, Michel
Dominguez, Marcel
Dugas, Brice
Genevois, Olivier
Guyomarch, Jérôme
Halfon, Jérémie
Hera, Ruxandra
Jankowski, Olivier
Klinger, Valérie
Koch, Edouard
Laib, Soumia
Le Lez, Marie-Laure
Lebreton, Olivier
Lecleire-Collet, Amélie
Marc, Caroline
Margescu, Victor
Mauget-Faÿsse, Martine
Milazzo, Solange
Montcriol, Anne-Lise
Nefzaoui, Chaker
Oubraham, Hassiba
Plavosin, Paul
Rebollo, Olivier
Ribstein, Gilles
Righini, Maud
Rothschild, Pierre-Raphaël
Rumen, Franck
Rysanek, Boris
Saleh, Maher
Sampo, Magali
Schauer, Philippe
Scheer, Sarah
Theron, Jean-Philippe
Zerbib, Jennyfer
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02924311 at ClinicalTrials.govDocuments that mention this clinical trial
Two-year outcomes of the APOLLON observational study of intravitreal aflibercept monotherapy in France in patients with diabetic macular edema
https://doi.org/10.1038/s41598-022-22838-1
-
Funding
Funding for this research was provided by:
Bayer Consumer Care AG, Basel, Switzerland
- License Information
-
More Information
Article History
Received: 29 June 2022
Accepted: 19 October 2022
First Online: 29 October 2022
Competing interests
: JFK has received consulting fees from AbbVie Allergan, Bayer, Carl Zeiss Meditec, Janssen, Kanghong, NanoRetina, Novartis, Novo Nordisk, Roche, and Théa. VD has received consulting fees from Bayer, Novartis, Théa, and Horus Pharma. CF has received consulting fees from Allergan, Bayer, and Novartis. RT has received grants and consulting fees from AbbVie Allergan, Bayer, and Novartis; has received consulting fees from Alcon, Apellis, Genentech, KHB, Iveric Bio, Oculis, Roche, and Théa; and his department has received non-financial support from Zeiss. AGA has received consulting fees from Allergan, Bayer, Novartis, and Optos. CD has received consulting fees from AbbVie, Bayer, Horus Pharma, and Novartis. LK has received consulting fees from AbbVie Allergan, Alcon, Bayer, Krystal Biotech, Novartis, Regeneron, and Théa. PM has received consulting fees from Allergan, Bayer, Horus Pharma, Merck Sharp & Dohme, Novartis, and Sanofi.
